Tokai Pharmaceuticals Inc. (TKAI) Fundamental Analysis & Valuation

NASDAQ:TKAI

Current stock price

0.61
-0.03 (-4.69%)
At close:
0.564
-0.05 (-7.54%)
After Hours:

This TKAI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

No Fundamental Analysis report for TKAI not available.

TKAI Fundamentals: All Metrics, Ratios and Statistics

Tokai Pharmaceuticals Inc.

NASDAQ:TKAI (5/10/2017, 8:13:03 PM)

After market: 0.564 -0.05 (-7.54%)

0.61

-0.03 (-4.69%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners10.97%
Inst Owner ChangeN/A
Ins Owners57.61%
Ins Owner Change0%
Market Cap13.81M
Revenue(TTM)N/A
Net Income(TTM)N/A
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpS1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.37%
ROE -101.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 100.27%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.6
Quick Ratio 10.6
Altman-Z -4.95
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.1%
EPS 3YN/A
EPS 5Y0%
EPS Q2Q%66.18%
EPS Next Y-3.48%
EPS Next 2Y50%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Tokai Pharmaceuticals Inc. / TKAI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Tokai Pharmaceuticals Inc. (TKAI) stock?

ChartMill assigns a fundamental rating of null / 10 to TKAI.


Can you provide the valuation status for Tokai Pharmaceuticals Inc.?

ChartMill assigns a valuation rating of null / 10 to Tokai Pharmaceuticals Inc. (TKAI). This can be considered as Overvalued.


How profitable is Tokai Pharmaceuticals Inc. (TKAI) stock?

Tokai Pharmaceuticals Inc. (TKAI) has a profitability rating of null / 10.


How financially healthy is Tokai Pharmaceuticals Inc.?

The financial health rating of Tokai Pharmaceuticals Inc. (TKAI) is null / 10.


What is the expected EPS growth for Tokai Pharmaceuticals Inc. (TKAI) stock?

The Earnings per Share (EPS) of Tokai Pharmaceuticals Inc. (TKAI) is expected to decline by -3.48% in the next year.